The FDA’s First Hearing On CBD Left Industry Confused And Concerned

No decision was made by the FDA, but CBD manufacturers are on alert

 The U.S. Food and Drug Administration’s first hearing on cannabidiol — CBD — left those involved in the booming new industry concerned for its future.

“In the 10 hours of testimony, I think the panel was given some good information and some bad information,” said Colleen Keahey Lanier, the executive director of the Hemp Industries Association. “So, it is a risk at this point.”

The hearing Friday was the FDA’s first step in determining how it will regulate CBD — a compound derived from the hemp plant that is being widely marketed and consumed across the country, but is unregulated.

In his opening remarks, acting FDA Commissioner Ned Sharpless expressed doubts about the compound’s safety.

To Read The Rest Of This Article On UPI, Click Here

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

CHAMPS CBD Report, or ‘CCR’, is a national daily online trade publication serving retailers of CBD products and accessories. News and information are geared strictly to select retail channels, with distribution limited to retailers that sell CBD products and wholesalers.


Stay informed with the most up-to-date industry news to help you grow your business: subscribe to our newsletter below!

Copyright © 2019 CHAMPS CBD Report. Terms & Conditions | Privacy Policy

To Top